Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group

por Stupp, R., Tosoni, A., Bromberg, J. E. C., Hau, P., Campone, M., Gijtenbeek, J., Frenay, M., Breimer, L., Wiesinger, H., Allgeier, A., van den Bent, M. J., Bogdahn, U., van der Graaf, W., Yun, H. J., Gorlia, T., Lacombe, D., Brandes, A. A.
Publicado 2011